Gela histological scoring system for post‐treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice

The International Extranodal Lymphoma Study Group (IELSG) promoted this study to determine the inter‐observer agreement in the application of the Groupe d' Etude des Lymphomes de l' Adulte (GELA) histological scoring system for evaluating residual disease in post‐treatment gastric biopsies of patients with gastric Mucosa‐Associated Lymphoid Tissue (MALT) lymphoma (GML). Twenty‐one patients with Helicobacter pylori ‐associated GML and treated with anti‐H. pylori therapies were considered. A total of 154 biopsy sets from follow‐up endoscopic procedures after H. pylori eradication were examined independently by seven pathologists from four European countries, following histological criteria suggested by the GELA scoring system. The overall concordance rate was 83% with a kappa value of 0·64, indicating a significant agreement among the seven observers. Most non‐concordant responses clustered across the border of complete remission (CR) and probable minimal residual disease (pMRD), a distinction that does not imply critical clinical impact. Accordingly, when the analysis considered CR/pMRD as a single entity, the responses showed an overall concordance rate of 89% with kappa value of 0·83, thus indicating a high degree of inter‐observer agreement. This study provides additional validation of the GELA histological grading system. This scheme can therefore be recommended in routine practice and deserves to be used in prospective clinical trials.

[1]  Nicholas I Batalis,et al.  Intravascular large B-cell lymphoma. , 2012, Archives of pathology & laboratory medicine.

[2]  F. Mégraud,et al.  EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT , 2011, Gut.

[3]  C. Copie-Bergman,et al.  Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial , 2009, British journal of haematology.

[4]  C. Copie-Bergman,et al.  MALT lymphoma pathology, initial diagnosis, and post-treatment evaluation , 2008 .

[5]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Chott,et al.  Reverse Transcription-PCR for t(11;18)(q21;q21) Staging and Monitoring in Mucosa-Associated Lymphoid Tissue Lymphoma , 2006, Clinical Cancer Research.

[7]  H. Stein,et al.  Wotherspoon criteria combined with B cell clonality analysis by advanced polymerase chain reaction technology discriminates covert gastric marginal zone lymphoma from chronic gastritis , 2006, Gut.

[8]  M. Stolte,et al.  Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Salar,et al.  Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  V. Abraira,et al.  Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t(11;18): a 10-year updated follow-up of a prospective study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  U. Jaeger,et al.  High Relapse Rate in Patients with MALT Lymphoma Warrants Lifelong Follow-up , 2005, Clinical Cancer Research.

[12]  F. Mégraud,et al.  Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue , 2005, Virchows Archiv.

[13]  M. Stolte,et al.  Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series , 2003, Gut.

[14]  C. Copie-Bergman,et al.  Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma , 2003, Gut.

[15]  F. Cavalli,et al.  Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. , 2002, Blood.

[16]  M. Du,et al.  Gastric MALT lymphoma: from aetiology to treatment. , 2002, The Lancet. Oncology.

[17]  M. Stolte,et al.  Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Stolte,et al.  Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. , 1997, Journal of the National Cancer Institute.

[19]  G. Zamboni,et al.  Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma of mucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both? , 1996, Blood.

[20]  T. C. Diss,et al.  Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori , 1993, The Lancet.

[21]  Jacob Cohen A Coefficient of Agreement for Nominal Scales , 1960 .

[22]  F. Naeim 33 – Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) , 2013 .